EligibleTrials

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

Recruiting · NCT07506876 · Interventional (participants receive a specific treatment) · Lead sponsor: Legacy Health System

View the official record on ClinicalTrials.gov →
Breast cancer

Interventions studied

Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

What this trial is about

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

4 locations listed across 2 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.